Slide 1: Third Quarter 2024 Results
THIRD QUARTER 2024 RESULTS November 2024
Slide 2: Disclaimer
Disclaimer Except for historical information contained herein, the matters set forth in this presentation are forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These forward looking statements are not based on historical fact
Slide 3: Agenda
Agenda Operational Updates Financial Highlights Strategic Deliverables & YTD Progress Q&A
Slide 4: Q3'24 Operational Updates
Q3’24 Operational Updates
Slide 5: Record-Breaking Revenue and Profits Through Strategic Mergers and Business Integration
Record-Breaking Revenue and Profits Through Strategic Mergers and Business Integration Robust Business Growth • Q3’24 revenue reaches NT$5.61 billion, setting a new historical high Global CDMO • Revenue increased 37% YoY and over 30% QoQ + As of Q3’24 end, the Group has signed 9 new clients and adde
Slide 6: Global CDMO – Growing Presence in the US Market Through Strategic Mergers
Global CDMO – Growing Presence in the US Market Through Strategic Mergers Plymouth + Maple Grove, Minnesota Oral Solids Oral Solid • hard-gelatin capsules (IR/MR) Tablets • tablets, coated/ uncoated (IR/DR/ER) Capsules Powders (oral and topical) + Packaging & Serialization Liquids (solutio
Slide 7: Global Commercial Sales – Expanding Product Portfolios & Target Markets for Diversification
Global Commercial Sales – Expanding Product Portfolios & Target Markets for Diversification Continued Portfolio • Successful integration of TWi and USL platforms. More than 80 commercial products, Expansion + Diversification including general generics, specialty generics, and PIV certified generic d
Slide 8: Q3'24 Financial Highlights
bell Contributing to Better Health All J@lO)(@ Over the World Q3'24 Financial Highlights
Slide 9: Q3'24 Growth Drivers and Revenue Breakdown
Q3’24 Growth Drivers and Revenue Breakdown Q3’24 Growth Drivers* Revenue Breakdown Global CDMO, Commerical , 32% Q3’24 = 68% NT$5,615mn Q3’23 = NT$3,075mn SW+BH 6% DLS 21% Branded NDA 4% Other US generics Specialty 50% 19% * BH + SW = Bora Health + SunWay 9 *Including output for internal operations
Slide 10: Q3'24 Financials
Q3’24 Financials Q3’24 recorded gross margin of 42%, operating margin of 22%, net margin of 26%. Results from operational efficiency and cost control are gradually becoming evident, Financial Highlights resulting in margins improvements compared to the previous quarter. Key Financials YoY QoQ (in NT
Slide 11: Strong Top & Bottom-line Performance – Cumulative Net Profit Has Already Exceeded FY'23
Strong Top & Bottom-line Performance – Cumulative Net Profit has Already Exceeded FY’23 Revenue (NT$ mn) Gross Profits (NT$ mn) 6,991 14,200 5,833 13,500 10,494 2,913 1,672 704 4,900 1,800 2020 2021 2022 2023 YT3Q24 GM (%) 39% 34% 28% 49% 43% 2020 2021 2022 2023 YT3Q24 Operating Income (NT$ mn) Net
Slide 12: Strategic Deliverables & YTD Progress
Strategic Deliverables & YTD Progress
Slide 13: "Dual Engine" Growth Strategy
“Dual Engine” Growth Strategy * TAIWAN CANADA ● Tainan Facility ● Mississauga Facility ● Zhunan Facility ● Taoyuan Facility USA ● Zhongli I&II Facility ● Plymouth & Maple Grove ● Baltimore Facility 保瑞集團 Global CDMO Global Commercial Sales Comprehensive CDMO Services Diversified Portfolio & Effective
Slide 14: Global CDMO – Baltimore Sterile Manufacturing Site Contributed NT$450m Revenue
Global CDMO – Baltimore Sterile Manufacturing Site Contributed NT$450m Revenue Global CDMO Highlights Baltimore +20 new Added 20 new products (molecules) 127,900* ft2 4 Lines ~300 Employees products and signed 9 new clients YTD. CDMO Sales Steady growth in CDMO and QoQ+30% acquired businesses. Passe
Slide 15: Global Commercial Sales – Continue Optimization of Product Portfolio
Global Commercial Sales – Continue Optimization of Product Portfolio Commercial Sales Highlights Global Strategy Added 7 new commercialized Specialty 7 Additional 19% products, including 2 Products proprietary products and 5 distributed products. Branded NDA 4% SW+BH Commercial Expanded the VIGADRON
Slide 16: Flagship Product Vigafyde
• Revolutionary product: Only premixed, ready-to-use vigabatrin liquid formulation. Better patient acceptability. • Enhanced safety and precision: Simplified dosing process for caregivers and enhanced likelihood of accurate administration. Flagship Product Vigafyde Vigabatrin 505(b)(2) • Clinically
Slide 17: Established a Leadership Position in Pediatric Rare Disease Market
Established a Leadership Position in Pediatric Rare Disease Market • Distributed via USL’s specialty pharmacy Vigadrone + Vigafyde channels. • Leader in IS rare disease treatment • VIGADRONE is the fastest growing product in USL • Broadened offerings in vigabatrin 505(b)(2) USL’s portfolio, offering
Slide 18: 2024 U.S. Footprint - Acquisitions & Strategic Alliance
2024 U.S. Footprint - Acquisitions & Strategic Alliance • Over 85% revenue derived in the US market. 2024/4 One of the front-runner Taiwanese companies to enter the U.S. Plymouth & Maple Grove, Minnesota • Employee count in North America has Manufacturing capabilities, surpassed those in Taiwan. dis
Slide 19: Largest CDMO and Pharma Manufacturer in Taiwan with Aggressive Global Growth Plan
LARGEST CDMO and Pharma manufacturer in Taiwan with aggressive global growth plan Experienced LEADERSHIP team STRONG GROWTH in with proven track record of delivering CDMO and Rx Market continues to results and consistently outperforming have high demand and attractive the market CAGR 保瑞集團 Bora Group